Michael P Wilczek
Overview
Explore the profile of Michael P Wilczek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korutla R, Tedder D, Brogan K, Milosevic M, Wilczek M, Shehadeh N, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002672
: This study uses Sankey diagrams to analyze treatment pathways in patients with peripheral artery disease (PAD), which is a vascular condition characterized by atherosclerotic occlusion of the arteries, particularly...
2.
Pike A, Amal S, Maginnis M, Wilczek M
Viruses
. 2025 Jan;
17(1).
PMID: 39861801
JC polyomavirus (JCPyV) establishes a persistent, asymptomatic kidney infection in most of the population. However, JCPyV can reactivate in immunocompromised individuals and cause progressive multifocal leukoencephalopathy (PML), a fatal demyelinating...
3.
Obeng B, Bennett L, West B, Wagner D, Fleming P, Tasker M, et al.
J Immunotoxicol
. 2025 Jan;
21(1):2443397.
PMID: 39815634
Cetylpyridinium chloride (CPC) is a quaternary ammonium antimicrobial used in numerous personal care products, human food, cosmetic products, and cleaning solutions. Yet, there is minimal published data on CPC effects...
4.
Obeng B, Bennett L, West B, Wagner D, Fleming P, Tasker M, et al.
bioRxiv
. 2024 Jul;
PMID: 39026716
Cetylpyridinium chloride (CPC) is a quaternary ammonium antimicrobial used in numerous personal care products, human food, cosmetic products, and cleaning solutions. Yet, there is minimal published data on CPC effects...
5.
High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection
Bond A, Crocker M, Wilczek M, DuShane J, Sandberg A, Bennett L, et al.
Antiviral Res
. 2024 Jan;
222:105817.
PMID: 38246207
JC polyomavirus (JCPyV) is a nonenveloped, double-stranded DNA virus that infects the majority of the population. Immunocompetent individuals harbor infection in their kidneys, while severe immunosuppression can result in JCPyV...
6.
Wong C, Wilczek M, Smith L, Bosse J, Richard E, Cavanaugh R, et al.
J Gerontol A Biol Sci Med Sci
. 2023 Jul;
78(11):2111-2118.
PMID: 37485864
Background: Despite known disparities in health status among older sexual and gender minority adults (OSGM), the prevalence of frailty is unknown. The aim of this study was to develop and...
7.
Mehmood K, Wilczek M, DuShane J, Parent M, Mayberry C, Wallace J, et al.
Viruses
. 2022 Dec;
14(12).
PMID: 36560603
The organization and dynamics of plasma membrane receptors are a critical link in virus-receptor interactions, which finetune signaling efficiency and determine cellular responses during infection. Characterizing the mechanisms responsible for...
8.
Wilczek M, Pike A, Craig S, Maginnis M, King B
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628509
JC polyomavirus (JCPyV) is the causative agent of the fatal, incurable, neurological disease, progressive multifocal leukoencephalopathy (PML). The virus is present in most of the adult population as a persistent,...
9.
Wilczek M, Armstrong F, Mayberry C, King B, Maginnis M
Cells
. 2021 Nov;
10(11).
PMID: 34831441
Astrocytes are a main target of JC polyomavirus (JCPyV) in the central nervous system (CNS), where the destruction of these cells, along with oligodendrocytes, leads to the fatal disease progressive...
10.
Wilczek M, Armstrong F, Geohegan R, Mayberry C, DuShane J, King B, et al.
Viruses
. 2021 Sep;
13(9).
PMID: 34578413
JC polyomavirus (JCPyV) is a neuroinvasive pathogen causing a fatal, demyelinating disease of the central nervous system (CNS) known as progressive multifocal leukoencephalopathy (PML). Within the CNS, JCPyV predominately targets...